Hypothalamic opioid-Melanocortin appetitive balance and addictive craving

Medical Hypotheses

Volumn 76, Issue 1, 2011, Pages 132-137

  Reece, Albert Stuart ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; AMFEBUTAMONE; CANNABINOID; CONTRAVE; MELANOCORTIN; MONOAMINE; NALOXONE; NALTREXONE; OPIATE; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG;

ALCOHOLISM; APPETITE; ARTICLE; AUTOMUTILATION; CANNABIS ADDICTION; COCAINE DEPENDENCE; DRUG USE; FOOD CRAVING; FOOD INTAKE; GENE LOCUS; HUMAN; HYPOTHALAMUS; NONHUMAN; OPIATE ADDICTION; PATHOLOGICAL GAMBLING; PROMOTER REGION; WEIGHT GAIN;

ANIMALS; APPETITE; HUMANS; HYPOTHALAMUS; MELANOCORTINS; MOTIVATION; OPIOID PEPTIDES; PRO-OPIOMELANOCORTIN; PROMOTER REGIONS, GENETIC; SUBSTANCE-RELATED DISORDERS;

EID: 78650172489     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.09.002     Document Type: Article

References (135)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington D.C.: American Psychiatric Association; 1994.
2. Kim S.W., Grant J.E., Adson D.E., Shin Y.C. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001, 49:914-921.
3. Mutschler J., Buhler M., Diehl A., Mann K., Kiefer F. Disulfiram, an old drug with new potential in the treatment of pathological gambling?. Med Hypotheses 2010, 74:209-210.
4. Tamminga C.A., Nestler E.J. Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 2006, 163:180-181.
5. Carr K.D., Chau L.S., Cabeza de Vaca S., Gustafson K., Stouffer M., Tukey D.S., et al. AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats. Neuroscience 2010, 165:1074-1086.
6. Nair S.G., Adams-Deutsch T., Epstein D.H., Shaham Y. The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking. Prog Neurobiol 2009, 89:18-45.
7. Page R.M., Brewster A. Depiction of food as having drug-like properties in televised food advertisements directed at children: portrayals as pleasure enhancing and addictive. J Pediatr Health Care 2009, 23:150-157.
8. Uslaner J.M., Dell'Orco J.M., Pevzner A., Robinson T.E. The influence of subthalamic nucleus lesions on sign-tracking to stimuli paired with food and drug rewards: facilitation of incentive salience attribution?. Neuropsychopharmacology 2008, 33:2352-2361.
9. Kronenberg H.M., Melmed S., Polonsky K.S., Larsen P.R. Williams Textbook of Endocrinology 2007, New York, Saunders Elsevier.
10. Guyton A.C., Hall J.E. Textbook of Physiology 2006, Philadelphia, Elsevier Saunders.
11. Matias I., Vergoni A.V., Petrosino S., Ottani A., Pocai A., Bertolini A., et al. Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 2008, 54:206-212.
12. Fowler J.S., Volkow N.D., Kassed C.A., Chang L. Imaging the addicted human brain. Science & Practice Perspectives/A Publication of the National Institute on Drug Abuse, National Institutes of Health 2007, 3:4-16.
13. Cami J., Farre M. Drug addiction. N Engl J Med 2003, 349:975-986.
14. Watkins L.R., Maier S.F. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29-57.
15. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., Watkins L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 2007, 7:98-111.
16. Watkins L.R., Hutchinson M.R., Ledeboer A., Wieseler-Frank J., Milligan E.D., Maier S.F. Norman cousins lecture. Glia as the " bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007, 21:31-146.
17. Watkins L.R., Hutchinson M.R., Milligan E.D., Maier S.F. " Listening" and " talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 2007, 56:148-169.
18. Fauci A.S., Braunwald E., Kapser D.L., Hauser S.L., Longo D.L., Jameson J.L. Harrison's Principles of Internal Medicine 2008, McGraw Hill, New York. 17th ed.
19. Nillni E.A. Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin. Endocrinology 2007, 148:4191-4200.
20. Barr C.S., Dvoskin R.L., Yuan Q., Lipsky R.H., Gupte M., Hu X., et al. CRH haplotype as a factor influencing cerebrospinal fluid levels of corticotropin-releasing hormone, hypothalamic-pituitary-adrenal axis activity, temperament, and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 2008, 65:934-944.
21. Li Q.L., Jansen E., Friedman T.C. Regulation of prohormone convertase 1 (PC1) by gp130-related cytokines. Mol Cel Endocrinol 1999, 158:143-152.
22. Auernhammer C.J., Kopp F.B., Vlotides G., Dorn F., Isele N.B., Spottl G., et al. Comparative study of gp130 cytokine effects on corticotroph AtT-20 cells-redundancy or specificity of neuroimmunoendocrine modulators?. Neuroimmunomodulation 2004, 11:224-232.
23. Iwasaki Y., Nishiyama M., Taguchi T., Kambayashi M., Asai M., Yoshida M., et al. Activation of AMP-activated protein kinase stimulates proopiomelanocortin gene transcription in AtT20 corticotroph cells. Am J Physiol Endocrinol Metab 2007, 292:E1899-E1905.
24. Asaba K., Iwasaki Y., Asai M., Yoshida M., Nigawara T., Kambayashi M., et al. High glucose activates pituitary proopiomelanocortin gene expression: possible role of free radical-sensitive transcription factors. Diabetes Metab Res Rev 2007, 23:317-323.
25. Yang G., Lim C.Y., Li C., Xiao X., Radda G.K., Cao X., et al. FoxO1 inhibits leptin regulation of pro-opiomelanocortin promoter activity by blocking STAT3 interaction with specificity protein 1. J Biol Chem 2009, 284:3719-3727.
26. Gao Q., Mezei G., Nie Y., Rao Y., Choi C.S., Bechmann I., et al. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat Med 2007, 13:89-94.
27. Jenks B.G. Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved. Ann NY Acad Sci 2009, 1163:17-30.
28. Plagemann A., Harder T., Brunn M., Harder A., Roepke K., Wittrock-Staar M., et al. Hypothalamic proopiomelanocortin promoter methylation becomes altered by early overfeeding: an epigenetic model of obesity and the metabolic syndrome. J physiol 2009, 587:4963-4976.
29. Renner U., De Santana E.C., Gerez J., Frohlich B., Haedo M., Pereda M.P., et al. Intrapituitary expression and regulation of the gp130 cytokine interleukin-6 and its implication in pituitary physiology and pathophysiology. Ann N Y Acad Sci 2009, 1153:89-97.
30. Iwasaki Y., Taguchi T., Nishiyama M., Asai M., Yoshida M., Kambayashi M., et al. Lipopolysaccharide stimulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocr J 2008, 55:285-290.
31. Kidane A.H., Heinrich G., Dirks R.P., de Ruyck B.A., Lubsen N.H., Roubos E.W., et al. Differential neuroendocrine expression of multiple brain-derived neurotrophic factor transcripts. Endocrinology 2009, 150:1361-1368.
32. Mynard V., Latchoumanin O., Guignat L., Devin-Leclerc J., Bertagna X., Barre B., et al. Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorylated 3′, 5′-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Mol Endocrinol 2004, 18:2997-3010.
33. Catania A., Gatti S., Colombo G., Lipton J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004, 56:1-29.
34. Bertolini A., Tacchi R., Vergoni A.V. Brain effects of melanocortins. Pharmacol Res 2009, 59:13-47.
35. Starowicz K., Przewlocka B. The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception. Life Sci 2003, 73:823-847.
36. Korner J., Leibel R.L. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003, 349:926-928.
37. Bomberg E.M., Grace M.K., Levine A.S., Olszewski P.K. Functional interaction between nociceptin/orphanin FQ and alpha-melanocyte-stimulating hormone in the regulation of feeding. Peptides 2006, 27:1827-1834.
38. Beckman T.R., Shi Q., Levine A.S., Billington C.J. Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia. Physiol Behav 2009, 96:568-573.
39. Shiraishi J., Yanagita K., Fujita M., Bungo T. Micro-opioid receptor agonist diminishes POMC gene expression and anorexia by central insulin in neonatal chicks. Neurosci Lett 2008, 439:227-229.
40. Chang S.H., Jung E.J., Lim D.G., Park Y.H., Wee Y.M., Kim J.H., et al. Anti-inflammatory action of alpha-melanocyte stimulating hormone (alpha-MSH) in anti-CD3/CD28-mediated spleen and CD4(+)CD25(-) T cells and a partial participation of IL-10. Immunol Lett 2008, 118:44-48.
41. Cooper A., Robinson S.J., Pickard C., Jackson C.L., Friedmann P.S., Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005, 175:4806-4813.
42. MacLeod A., Tweedie A., McLellan S., Hope M., Taylor S., Cooper A., et al. Allelic segregation and independent assortment in T. brucei crosses: proof that the genetic system is Mendelian and involves meiosis. Mol Biochem Parasitol 2005, 143:12-19.
43. Gonzalez P.V., Schioth H.B., Lasaga M., Scimonelli T.N. Memory impairment induced by IL-1beta is reversed by alpha-MSH through central melanocortin-4 receptors. Brain Behav Immun 2009, 23:817-822.
44. Luger T.A., Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis 2007, 66(Suppl. 3):iii52-iii55.
45. Vrinten D.H., Adan R.A., Groen G.J., Gispen W.H. Chronic blockade of melanocortin receptors alleviates allodynia in rats with neuropathic pain. Anesth Analg 2001, 93:1572-1577.
46. Vrinten D.H., Kalkman C.J., Adan R.A., Gispen W.H. Neuropathic pain: a possible role for the melanocortin system?. Eur J Pharmacol 2001, 429:61-69.
47. Vrinten D.H., Gispen W.H., Kalkman C.J., Adan R.A. Interaction between the spinal melanocortin and opioid systems in a rat model of neuropathic pain. Anesthesiology 2003, 99:449-454.
48. Starowicz K., Sieja A., Bilecki W., Obara I., Przewlocka B. The effect of morphine on MC4 and CRF receptor mRNAs in the rat amygdala and attenuation of tolerance after their blockade. Brain Res 2003, 990:113-119.
49. Ogawa T., Shishioh-Ikejima N., Konishi H., Makino T., Sei H., Kiryu-Seo S., et al. Chronic stress elicits prolonged activation of alpha-MSH secretion and subsequent degeneration of melanotroph. J Neurochem 2009, 109:1389-1399.
50. List J.F., Habener J.F. Defective melanocortin 4 receptors in hyperphagia and morbid obesity. N Engl J Med 2003, 348:1160-1163.
51. Sinno M.H., Do Rego J.C., Coeffier M., Bole-Feysot C., Ducrotte P., Gilbert D., et al. Regulation of feeding and anxiety by alpha-MSH reactive autoantibodies. Psychoneuroendocrinology 2009, 34:140-149.
52. Dyer K.R., White J.M. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997, 92:1445-1455.
53. Callaly T., Trauer T., Munro L., Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry 2001, 35:601-605.
54. Reece A.S. Chronology and patterns of psychiatric morbidity in substance dependent and medical patients. Australas Psychiatry 2009, 17:170-171.
55. Levine A.S. The animal model in food intake regulation: examples from the opioid literature. Physiol Behav 2006, 89:92-96.
56. Gosnell B.A., Levine A.S. Reward systems and food intake: role of opioids. Int J Obe (2005) 2009, 33(Suppl. 2):S54-S58.
57. Childs A. Naltrexone in organic bulimia: a preliminary report. Brain Inj 1987, 1:49-55.
58. Olszewski P.K., Shaw T.J., Grace M.K., Hoglund C.E., Fredriksson R., Schioth H.B., et al. Complexity of neural mechanisms underlying overconsumption of sugar in scheduled feeding: involvement of opioids, orexin, oxytocin and NPY. Peptides 2009, 30:226-233.
59. Will M.J., Pratt W.E., Kelley A.E. Pharmacological characterization of high-fat feeding induced by opioid stimulation of the ventral striatum. Physiol Behav 2006, 89:226-234.
60. Levine A.S., Billington C.J. Opioids as agents of reward-related feeding: a consideration of the evidence. Physiol Behav 2004, 82:57-61.
61. Kelley A.E., Bakshi V.P., Haber S.N., Steininger T.L., Will M.J., Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 2002, 76:365-377.
62. Grossman H.C., Hadjimarkou M.M., Silva R.M., Giraudo S.Q., Bodnar R.J. Interrelationships between mu opioid and melanocortin receptors in mediating food intake in rats. Brain Res 2003, 991:240-244.
63. Kalange A.S., Kokare D.M., Singru P.S., Upadhya M.A., Chopde C.T., Subhedar N.K. Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia. Brain Res 2007, 1181:10-20.
64. Starowicz K., Obara I., Przewlocki R., Przewlocka B. Inhibition of morphine tolerance by spinal melanocortin receptor blockade. Pain 2005, 117:401-411.
65. Zheng H., Patterson L.M., Berthoud H.R. Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. J Neurosci 2007, 27:11075-11082.
66. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 2009, 284:6530-6535.
67. Oertel B., Lotsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008, 9:179-194.
68. Mogil J.S., Ritchie J., Smith S.B., Strasburg K., Kaplan L., Wallace M.R., et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005, 42:583-587.
69. Starowicz K., Przewlocki R., Gispen W.H., Przewlocka B. Modulation of melanocortin-induced changes in spinal nociception by mu-opioid receptor agonist and antagonist in neuropathic rats. Neuroreport 2002, 13:2447-2452.
70. Polidori C., Geary N., Massi M. Effect of the melanocortin receptor stimulation or inhibition on ethanol intake in alcohol-preferring rats. Peptides 2006, 27:144-149.
71. Olszewski P.K., Wirth M.M., Grace M.K., Levine A.S., Giraudo S.Q. Evidence of interactions between melanocortin and opioid systems in regulation of feeding. Neuroreport 2001, 12:1727-1730.
72. Ercil N.E., Galici R., Kesterson R.A. HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology (Berl) 2005, 180:279-285.
73. Kokare D.M., Singru P.S., Dandekar M.P., Chopde C.T., Subhedar N.K. Involvement of alpha-melanocyte stimulating hormone (alpha-MSH) in differential ethanol exposure and withdrawal related depression in rat: neuroanatomical-behavioral correlates. Brain Res 2008, 1216:53-67.
74. Hutchinson M.R., Zhang Y., Shridhar M., Evans J.H., Buchanan M.M., Zhao T.X., et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83-95.
75. Watkins L.R., Hutchinson M.R., Rice K.C., Maier S.F. The " Toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009, 30:581-591.
76. Adler M.W., Geller E.B., Chen X., Rogers T.J. Viewing chemokines as a third major system of communication in the brain. AAPS J 2005, 7:E865-E870.
77. Patel J.P., Sengupta R., Bardi G., Khan M.Z., Mullen-Przeworski A., Meucci O. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol 2006, 12:492-500.
78. Holan V., Zajicova A., Krulova M., Blahoutova V., Wilczek H. Augmented production of proinflammatory cytokines and accelerated allotransplantation reactions in heroin-treated mice. Clin Exp Immunol 2003, 132:40-45.
79. Brunton L.L., Lazo J.S., Parker K.L. Goodman and Gilman's the Pharmacologic Basis of Therapeutics 2006, McGraw Hill, New York. 11th ed.
80. Sadeghian S., Darvish S., Davoodi G., Salarifar M., Mahmoodian M., Fallah N., et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007, 14:715-717.
81. Ceriello A., Giugliano D., Passariello N., Quatraro A., Dello Russo P., Torella R., et al. Impaired glucose metabolism in heroin and methadone users. Hormone and Metabolic Research. Hormon-und Stoffwechselforschung 1987, 19:430-433.
82. Neri S., Bruno C.M., Pulvirenti D., Malaguarnera M., Italiano C., Mauceri B., et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl) 2005, 179:700-704.
83. Queensland Government. Queensland Opioid Treatment Program Clinical Guidelines. 1st ed. Brisbane: Queensland Government; 2009.
84. Housova J., Wilczek H., Haluzik M.M., Kremen J., Krizova J., Haluzik M. Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiological Research/Academia Scientiarum Bohemoslovaca 2005, 54:73-78.
85. Liu L., Hutchinson M.R., White J.M., Somogyi A.A., Coller J.K. Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenet Genomics 2009, 19:869-876.
86. Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab 1983, 12:725-746.
87. Cushman P., Bordier B., Hilton J.G. Hypothalamic-pituitary-adrenal axis in methadone-treated heroin addicts. J Clin Endocrinol Metab 1970, 30:24-29.
88. Buckingham J.C., Cooper T.A. Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 1984, 38:411-417.
89. Chang S.L., Patel N.A., Romero A.A., Thompson J., Zadina J.E. FOS expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res 1996, 736:227-236.
90. Zhou Y., Spangler R., Maggos C.E., LaForge K.S., Ho A., Kreek M.J. Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur J Pharmacol 1996, 315:31-35.
91. Zhang G.F., Ren Y.P., Sheng L.X., Chi Y., Du W.J., Guo S., et al. Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: effects of acute and protracted abstinence. Am J Drug Alcohol Abuse 2008, 34:760-768.
92. Willenbring M.L., Morley J.E., Krahn D.D., Carlson G.A., Levine A.S., Shafer R.B. Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology 1989, 14:371-391.
93. Davis C.A., Levitan R.D., Reid C., Carter J.C., Kaplan A.S., Patte K.A., et al. Dopamine for " wanting" and opioids for " liking": a comparison of obese adults with and without binge eating. Obesity (Silver Spring Md) 2009, 17:1220-1225.
94. Erlanson-Albertsson C. Sugar triggers our reward-system. Sweets release opiates which stimulates the appetite for sucrose-insulin can depress it. Lakartidningen 2005, 102:1620-1622, 1625, 1627.
95. Erlanson-Albertsson C. How palatable food disrupts appetite regulation. Basic Clin Pharmacol Toxicol 2005, 97:61-73.
96. Howard A.A., Floris-Moore M., Arnsten J.H., Santoro N., Fleischer N., Lo Y., et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005, 40:1492-1499.
97. Howard A.A., Floris-Moore M., Lo Y., Arnsten J.H., Fleischer N., Klein R.S. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Medicine 2006, 7:389-396.
98. Kolarzyk E., Pach D., Wojtowicz B., Szpanowska-Wohn A., Szurkowska M. Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przeglad Lekarski 2005, 62:373-377.
99. Curran H.V., Bolton J., Wanigaratne S., Smyth C. Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999, 94:665-674.
100. Oviedo-Joekes E., Brissette S., Marsh D.C., Lauzon P., Guh D., Anis A., et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009, 361:777-786.
101. Musshoff F., Lachenmeier K., Lichtermann D., Madea B. Cocaine and opiate concentrations in hair from subjects in a heroin maintenance program in comparison to a methadone substituted group. Int J Legal Med 2009, 123:363-369.
102. Musshoff F., Trafkowski J., Lichtermann D., Madea B. Comparison of urine results concerning co-consumption of illicit heroin and other drugs in heroin and methadone maintenance programs. Int J Legal Med 2009, [Epub ahead of print].
103. Disney E.R., Kidorf M., King V.L., Neufeld K., Kolodner K., Brooner R.K. Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 2005, 79:23-32.
104. Backmund M., Meyer K., Henkel C., Soyka M., Reimer J., Schutz C.G. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis 2005, 24:17-29.
105. Hallinan R., Crettol S., Agho K., Attia J., Besson J., Croquette-Krokar M., et al. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. Eur J Clin Pharmacol 2009, 65:1113-1120.
106. Budney A.J., Bickel W.K., Amass L. Marijuana use and treatment outcome among opioid-dependent patients. Addiction 1998, 93:493-503.
107. Humeniuk R., Ali R., McGregor C., Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003, 98:413-418.
108. Darke S., Ross J., Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996, 43:191-198.
109. Wu L.T., Blazer D.G., Stitzer M.L., Patkar A.A., Blaine J.D. Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study. Am J Addict 2008, 17:304-311.
110. Bruce R.D. Medical interventions for addictions in the primary care setting. Top HIV Med 2010, 18:8-12.
111. Greenway F.L., Dunayevich E., Tollefson G., Erickson J., Guttadauria M., Fujioka K., et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009, 94:4898-4906.
112. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring, Md) 2009, 17:30-39.
113. Halford J.C., Boyland E.J., Blundell J.E., Kirkham T.C., Harrold J.A. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010, 6:255-269.
114. Lee M.W., Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 2009, 10:1841-1845.
115. Plodkowski R.A., Nguyen Q., Sundaram U., Nguyen L., Chau D.L., St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009, 10:1069-1081.
116. Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs 2009, 10:1117-1125.
117. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R., et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict behav 2008, 33:651-667.
118. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., O'Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 1999, 16:163-167.
119. Oslin D., Liberto J.G., O'Brien J., Krois S., Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997, 5:324-332.
120. Volpicelli J.R., Volpicelli L.A., O'Brien C.P. Medical management of alcohol dependence. clinical use and limitations of naltrexone treatment. Alcohol Alcohol 1995, 30:789-798.
121. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876-880.
122. Kim S.W., Grant J.E. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001, 16:285-289.
123. Schmitz J.M., Lindsay J.A., Green C.E., Herin D.V., Stotts A.L., Gerard Moeller F. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009, 18:356-362.
124. Haggkvist J., Lindholm S., Franck J. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addict Biol 2009, 14:260-269.
125. Todtenkopf M.S., O'Neill K.S., Kriksciukaite K., Turncliff R.Z., Dean R.L., Ostrovsky-Day I., et al. Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats. Addict Biol 2009, 14:408-418.
126. Haggkvist J., Lindholm S., Franck J. The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res 2009, 197:219-224.
127. Kars H., Broekema W., Glaudemans-van Gelderen I., Verhoeven W.M., van Ree J.M. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psychiatry 1990, 27:741-746.
128. Smith K.C., Pittelkow M.R. Naltrexone for neurotic excoriations. J Am Acad Dermatol 1989, 20:860-861.
129. Lienemann J., Walker F.D. Reversal of self-abusive behavior with naltrexone. J Clin Psychopharmacol 1989, 9:448-449.
130. Lienemann J., Walker F. Naltrexone for treatment of self-injury. Am J Psychiatry 1989, 146:1639-1640.
131. Barrett R.P., Feinstein C., Hole W.T. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989, 93:644-651.
132. Justinova Z., Tanda G., Munzar P., Goldberg S.R. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 2004, 173:186-194.
133. Farren C.K., O'Malley S., Grebski G., Maniar S., Porter M., Kreek M.J. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Alcohol Clin Exp Res 1999, 23:502-508.
134. United Nations Office of Drugs and Crime. World Drug Report 2009, UN ODC, Vienna; 2009.
135. Joint United Nationals Program on HIV/AIDS (UNAIDS), 2008. Report on the Global AIDS Epidemic, UNAIDS, Geneva; 2008.